Cerenome Inks HCSC Deal, Surpasses 150M Covered Lives for CNSide
CNSY sits 36% above its 52-week low of $2.9.
Summary
Cerenome's CNSide Diagnostics signed an in-network agreement with Health Care Service Corporation (HCSC), effective August 1, 2026, adding approximately 27.3 million commercial and Medicare Advantage covered lives. Combined with prior agreements, CNSide now has contracted access to roughly 153 million covered lives, exceeding the company's full-year 2026 coverage objective ahead of schedule. This is a material commercial milestone for a micro-cap diagnostics company—broad payer coverage is the key driver of physician adoption and test utilization for laboratory-developed tests. The agreement follows the company's recent name change from Plus Therapeutics to Cerenome (8-K filed August 4, 2026), signaling a strategic pivot toward CNS oncology diagnostics. With over 11,000 tests performed at 120+ institutions since 2020, the expanded coverage could accelerate revenue growth, though actual utilization and reimbursement rates remain to be seen.
At the time of this announcement, CNSY was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.5M. The 52-week trading range was $2.90 to $23.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.